The limited data available suggests modest to poor responses for patients with NSCLC ERBB2 and ROS1-driven tumors receiving ICI monotherapy or combination therapy, regardless of PD-L1 expression or TMB status, indicating additional co-mutations and other factors may play a role. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.